Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03943875
PHASE4

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Sponsor: The University of Texas Medical Branch, Galveston

View on ClinicalTrials.gov

Summary

The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.

Key Details

Gender

All

Age Range

15 Years - 26 Years

Study Type

INTERVENTIONAL

Enrollment

767

Start Date

2019-06-17

Completion Date

2026-03-01

Last Updated

2026-03-12

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

9-valent HPV vaccine, 2 dose efficacy

Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.

BIOLOGICAL

9-valent HPV vaccine, 3 doses standard timing

Will be comparison group for 2 dose efficacy group.

Locations (1)

University of Texas Medical Branch

Galveston, Texas, United States